๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hepatitis C virus genotypes and the development of hepatocellular carcinoma

โœ Scribed by Dobrila STANKOVIC-DJORDJEVIC; Nebojsa DJORDJEVIC; Gordana TASIC; Marina DINIC; Aleksandar KARANIKOLIC; Milica PESIC

Book ID
108988705
Publisher
Wiley (Blackwell Publishing)
Year
2007
Tongue
English
Weight
66 KB
Volume
8
Category
Article
ISSN
1751-2972

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Hepatitis C virus genotype 1b and risk o
Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma
โœ R Romeo; M G Rumi; N i Del; M Colombo ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 138 KB ๐Ÿ‘ 2 views

Hepatitis C Virus Genotype 1b and Risk of Hepatocellular Carcinoma and high baseline AFP were the only variables independently To the Editor: correlated with the risk of developing HCC. Thus, our prospective study, based on a larger number of We read with interest the article by Bruno et al. (p. 75

Hepatitis C virus genotypes and risk of
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study
โœ S Bruno; E Silini; A Crosignani; F Borzio; G Leandro; F Bono; M Asti; S Rossi; A ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 187 KB ๐Ÿ‘ 2 views

approximately 3%. 3,4 Early detection of HCC in cirrhotic pa-A prospective study was performed to establish tients can usually be achieved by screening with noninvasive whether infection with specific hepatitis C virus (HCV) techniques, such as ultrasound (US) scan and serum a-fetogenotypes was ass

Hepatitis B and C virus and hepatocellul
Hepatitis B and C virus and hepatocellular carcinoma
โœ I.O. Olubuyide; B. Aliyu; O.A. Olalelye; S.O. Ola; F. Olawuyi; U.H. Malabu; S.O. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 478 KB

Antibody to hepatitis C virus (anti-HCV) was detected in 18.7% of patients with hepatocellular carcinoma (HCC) and in 10.9% of controls (P<O.OOl). The corresponding prevalences of hepatitis B surface antigen (HBsAg) were 59.3% and 50.0% (F'CO.001). Using patients with non-hepatic disease as controls